A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated RejectionKatharina A. Mayer, Georg A. Böhmig, Alexander Kainz et al.|New England Journal of Medicine|2024Cited by 151
Natural Killer Cell Presence in Antibody-Mediated RejectionMatthias Diebold, Georg A. Böhmig, Evan A. Farkash et al.|Transplant International|2024Cited by 19
Deletion of the Natural Killer Cell Receptor NKG2C Encoding KLR2C Gene and Kidney Transplant OutcomeHannes Vietzen, Georg A. Böhmig, Bernd Döhler et al.|Frontiers in Immunology|2022Cited by 18
225.3: Randomized phase 2 trial of felzartamab in humoral transplant rejection.Katharina A. Mayer, Georg A. Böhmig, Eva Schrezenmeier et al.|Transplantation|2024Cited by 0